Skip to main content
. 2018 Apr 24;18:300. doi: 10.1186/s12913-018-3095-9

Table 2.

Clinical Characteristics, by PN Reimbursement Status

Parameter Patients with PN Reimbursement
(N = 142)
Patients without PN Reimbursement
(N = 258)
p-value*
Type of diabetesa
 Type 1 (%) 4 (2.8) 22 (8.6) 0.0260
 Type 2 (%) 138 (97.2) 235 (91.4)
Duration of time with diabetes (years)
 Mean (SD) 11.8 (7.3) 11.8 (7.7) 0.9750
 Median (Q1, Q3) 11 (7, 15) 11 (5, 16)
HbA1c
 Mean (SD) 8.0 (1.5) 8.0 (1.8) 0.7484
 Median (Q1, Q3) 7.6 (6.8, 8.9) 7.6 (6.8, 8.8)
Glucose controla
 HbA1c < 7% (%) 43 (30.3) 81 (31.4) 0.8177
 HbA1c ≥ 7% (%) 99 (69.7) 177 (68.6)
BMI
 Mean (SD) 25.1 (3.1) 25.6 (3.2) 0.0951
 Median (Q1, Q3) 24.8 (22.7, 27.1) 25.4 (23.5, 27.6)
Frequency of hypoglycemia in previous six monthsa
 0 (%) 60 (42.3) 104 (40.5) 0.4695
 1–2 (%) 42 (29.6) 66 (25.7)
 3+ (%) 40 (28.2) 87 (33.9)
Duration of insulin therapy (years)
 Mean (SD) 5.9 (5.0) 5.4 (4.3) 0.4444
 Median (Q1, Q3) 5 (2, 8) 4 (2, 8)
Presence of CVD (% Yes) 87 (61.3) 103 (39.9) <  0.0001
Presence of hyperlipidemiaa (% Yes) 77 (54.2) 48 (18.6)) <  0.0001
Presence of lipohypertrophya (% Yes) 59 (41.6) 153 (59.3) 0.0007
Number of lipohypertrophy nodes
 Mean (SD) 1.5 (0.7) 2.7 (2.5) <  0.0001
 Median (Q1, Q3) 1 (1, 2) 2 (1, 3)
Longest diameter of lipohypertrophy nodes
 Mean (SD) 16.8 (18.6) 16.1 (11.9) 0.1224
 Median (Q1, Q3) 10 (5, 22) 15 (8, 20)

*Differences in continuous variables were tested using Wilcoxon Rank Sum tests for non-normally distributed variables and the Student t-test for normally distributed variables; differences in categorical variables were tested using χ2 tests; p-values < 0.05 were considered significant

aPercentages represent column percentages

CVD Cardiovascular disease, HbA1c Hemoglobin A1c, Q1 Lower 25th percentile, Q3 Upper 25th percentile, SD Standard deviation